Parabilis Medicines, a clinical-stage biopharmaceutical company, announced the pricing of its upsized initial public offering (IPO) of 33.5 million shares at $20 each, expected to raise approximately $670 million. Additionally, Parabilis agreed to a concurrent private placement of 4.17 million shares to Regeneron Pharmaceuticals at $18 per share, expected to bring in about $75 million. The IPO shares will begin trading on Nasdaq under the ticker PBLS on June 10, 2026, with the offering closing around June 11, subject to customary conditions. This capital raise supports Parabilis' development of novel medicines targeting difficult protein targets in human disease.
On September 10, 2026, the Dow Jones, S&P 500, and Nasdaq all declined by 0.4%. The drop was driven by investor worries about rising oil prices and persistent inflation pressures. These factors raise concerns about economic growth and corporate profi...
Designer Brands Inc. reported Q2 earnings of $0.34 per share, beating estimates by 36%, but revenue fell 1.2% year-over-year to $730.63 million, missing expectations. The company improved profitability with an expanded adjusted gross margin of 47.9%,...
The Lovesac Company reported a better-than-expected Q2 earnings per share (EPS) of -$0.35, beating estimates by over 10% and improving from a -$0.45 loss a year ago. Despite this EPS beat, the company's revenue of $161.25 million narrowly missed anal...
Copart, Inc. is set to report its Q3 earnings with analysts expecting an EPS of $0.38, down from $0.41 last year, while revenue is projected to increase slightly to $1.14 billion from $1.13 billion. The company faces headwinds from a weak US market a...
Agree Realty Director Rakolta has purchased 20,136 shares of the company, investing approximately $1.5 million. This insider buying could signal confidence in the company's future prospects. Investors may view this as a positive sign, potentially imp...
